New CAR-T Therapy Offers Notable Results, Potential Payer Challenges – Atlantic Information Services, Inc.
|
New CAR–T Therapy Offers Notable Results, Potential Payer Challenges
Atlantic Information Services, Inc. 7), the agency hit another milestone with the approval of the first chimeric antigen receptor T cell (CAR-T) therapy. Novartis Pharmaceuticals Corp.'s Kymriah (tisagenlecleucel) has shown impressive results in clinical trials, but payers will face a … The FDA has just approved the revolutionary genetic modification treatment |
